Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

By D. Cunningham, I. Chau, D. Stocken, J. Valle, David B. Smith, W. Steward, P. Harper, J. Dunn, C. Tudur-Smith, J. West and 10 more. Journal of Clinical Oncology, 2009

747 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/7f7660ddbabfe3f9b48ea73826ab697225a63b01

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

K. Frese
elliot k fishman
D. Tuveson
C. Feig
A. Klein
J. Herman
A. Neesse
R. Hruban

Citations in the corpus

nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. (2015, unknown): “KPS 90-100 n = 241 n = 241 KPS 70-80 n = 164† n = 146 Neutropenia All treated 297 (73) 43 (11) 101 (25) 107 (26) 46 (11) 225 (58) 35 (9) 86 (22) 83 (21) 21 (5) KPS 90-100 185 (77) 22 (9) 65 (27) 67 (28) 31 (13) 156 (65) 20 (8) 60 (25) 60 (25) 16 (7) KPS 70-80 112 (68) 21 (13) 36 (22) 40 (24) 15 (9) ”
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. (2021, result): “A randomized study in 533 patients with advanced disease found that PFS and objective response rates were significantly improved in patients receiving gemcitabine plus capecitabine when compared with gemcitabine alone, although a trend toward an improvement in OS for the combination arm did not reac”
Stromal biology and therapy in pancreatic cancer (2010, background): “Notably, a recent phase III trial revealed a trend towards improved overall survival, and a meta-analysis involving 935 patients showed a significant survival benefit for the combination of capecitabine and gemcitabine.(84) Until recently, the mechanism for the extremely poor responsiveness to thera”
Recent progress in pancreatic cancer (2013, background): “…6.2 (P 5 .85) 21 vs 20 (P 5 .72) Louvet et al (2005),196 N 5 313 Gem vs Gem (FDR1 1 Oxaliplatin) 17.3 vs 26.8 (P 5 .04) 7.1 vs 9 (P 5 .13) 28 vs 35 Cunningham et al (2009),195 N 5 533 Gem 6 Capecitabine 14 vs 7 (P 5 .008) 7.4 vs 6 (P< .05) 26 vs 19 CALGB (2009),239 N 5 259 Gem/Cis 11 6.7 Gem…”